Notz, Quirin http://orcid.org/0000-0002-4042-4436
Heyland, Daren K.
Lee, Zheng-Yii
Menger, Johannes
Herrmann, Johannes
Chillon, Thilo S.
Fremes, Stephen
Mohammadi, Siamak
Elke, Gunnar
Mazer, C. David
Hill, Aileen
Velten, Markus
Ott, Sascha
Kleine-Brueggeney, Maren
Meybohm, Patrick
Schomburg, Lutz
Stoppe, Christian
Funding for this research was provided by:
Universitätsklinikum Würzburg
Article History
Received: 30 September 2023
Accepted: 28 November 2023
First Online: 8 December 2023
Declarations
:
: The ethics approval of the SUSTAIN CSX trial applies for this nested substudy. The original protocol was approved by the ethics committees of Queens University, Canada, and RWTH Aachen University, Germany, the German Federal Institute for Drugs and Medical Devices, and by all participating centers. Each patient gave written informed consent to participate in the study before surgery.
: Not applicable.
: Outside of this work, the authors disclose the following relationships: SF: payments to the institution (Canadian Institutes of Health Research, National Institute of Health, Medtronic, Boston Scientific, Amgen), participation on advisory board (PolyPid). GE: honoraria and travel support (Fresenius Kabi, Baxter). AH: grants (Deutsche Forschungsgemeinschaft, Fresenius Kabi, Pascoe), honoraria and travel support (Fresenius Kabi, Baxter). LS: grants (Deutsche Forschungsgemeinschaft), pending patent application for selenium status analysis, shareholder (selenOmed GmbH). CS: consulting fees and honoraria (Baxter, Fresenius, BBRAUN). The other authors have nothing to disclose.